Exploring the screening capacity of the Fear of Cancer Recurrence Inventory-Short Form for clinical levels of fear of cancer recurrence
Exploring the screening capacity of the Fear of Cancer Recurrence Inventory-Short Form for clinical levels of fear of cancer recurrence
复制标题
DOI：
10.1002/pon.4516
复制
发表时间：
2018-02-01
期刊：
影响因子：
3.6
通讯作者：
Butow, Phyllis
中科院分区：
文献类型：
--
作者：
Fardell, Joanna E.;Jones, Georden;Butow, Phyllis
癌症复发恐惧（fear of cancer recurrence， FCR）是癌症幸存者普遍关注的问题。鉴别具有临床显著FCR的幸存者需要有效的筛查措施和临床切断。我们在2个样本中评估了对癌症复发的恐惧清单-短表（FCRI-SF）临床分界点。方法将研究1参与者（来自澳大利亚随机对照试验：征服者恐惧）的FCR水平与FCR - sf评分进行比较。根据生物心理社会访谈，临床医生将参与者分为非临床、亚临床或临床FCR。研究2的参与者（来自加拿大FCR - english验证研究）通过使用FCR的半结构化临床访谈（SIFCR）将其分为临床或非临床FCR。受试者工作特征分析评估了FCRI-SF相对于临床评分（研究1）和SIFCR（研究2）的筛查能力。结果共1167例癌症幸存者（平均年龄53岁，SD=10.1）参与研究。临床医生认为43%的人有临床FCR。在研究2中，40名癌症幸存者（平均年龄：68岁，SD=7.0）参与；根据SIFCR， 25%符合临床FCR标准。在研究1和2中，受试者操作特征分析表明，FCR - sf识别具有临床FCR水平的癌症幸存者的截止值为22，具有足够的敏感性和特异性。结论建立FCR筛查措施的临床分界点对个性化护理和开展严谨的研究至关重要。我们的研究结果建议使用比以前报道的更高的FCR - sf临界值来识别临床显著的FCR。需要在不同的癌症人群中继续评估和验证FCRI-SF临界值。
ObjectiveFear of cancer recurrence (FCR) is a common concern among cancer survivors. Identifying survivors with clinically significant FCR requires validated screening measures and clinical cut-offs. We evaluated the Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) clinical cut-off in 2 samples.MethodsLevel of FCR in study 1 participants (from an Australian randomized controlled trial: ConquerFear) was compared with FCRI-SF scores. Based on a biopsychosocial interview, clinicians rated participants as having nonclinical, subclinical, or clinical FCR. Study 2 participants (from a Canadian FCRI-English validation study) were classified as having clinical or nonclinical FCR by using the semistructured clinical interview for FCR (SIFCR). Receiver operating characteristic analyses evaluated the screening ability of the FCRI-SF against clinician ratings (study 1) and the SIFCR (study 2).ResultsIn study 1, 167 cancer survivors (mean age: 53years, SD=10.1) participated. Clinicians rated 43% as having clinical FCR. In study 2, 40 cancer survivors (mean age: 68years, SD=7.0) participated; 25% met criteria for clinical FCR according to the SIFCR. For both studies 1 and 2, receiver operating characteristic analyses suggested a cut-off 22 on the FCRI-SF identified cancer survivors with clinical levels of FCR with adequate sensitivity and specificity.ConclusionsEstablishing clinical cut-offs on FCR screening measures is crucial to tailoring individual care and conducting rigorous research. Our results suggest using a higher cut-off on the FCRI-SF than previously reported to identify clinically significant FCR. Continued evaluation and validation of the FCRI-SF cut-off is required across diverse cancer populations.